|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results indicate that pharmacological MGAT2 inhibition modulates fat-induced gut peptide release and fat intake in normal mice and improves obesity and diabetes in HFD-fed ob/ob mice and thus may have potential for development into a treatment of obesity and its related metabolic diseases.
|
31837122 |
2020 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Mice without a functional gene encoding MGAT2 (Mogat2(-/-)) are protected from diet-induced obesity.
|
24784138 |
2014 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
To determine whether MGAT2 deficiency protects against obesity in the absence of high-fat feeding, we crossed Mogat2(-/-) mice with genetically obese Agouti mice.
|
21734185 |
2011 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we further investigate the effects of MGAT2 inhibition on 1) fat-induced gut peptide release and fat intake in normal mice and 2) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB).
|
31837122 |
2020 |
|
Metabolic Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Indeed, mice lacking the enzyme (Mogat2(-/-)) are resistant to obesity and other metabolic disorders induced by high-fat feeding.
|
21734185 |
2011 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicate that pharmacological MGAT2 inhibition modulates fat-induced gut peptide release and fat intake in normal mice and improves obesity and diabetes in HFD-fed ob/ob mice and thus may have potential for development into a treatment of obesity and its related metabolic diseases.
|
31837122 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
These results indicate that pharmacological MGAT2 inhibition modulates fat-induced gut peptide release and fat intake in normal mice and improves obesity and diabetes in HFD-fed ob/ob mice and thus may have potential for development into a treatment of obesity and its related metabolic diseases.
|
31837122 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we further investigate the effects of MGAT2 inhibition on 1) fat-induced gut peptide release and fat intake in normal mice and 2) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB).
|
31837122 |
2020 |
|
Obesity, Morbid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we further investigate the effects of MGAT2 inhibition on 1) fat-induced gut peptide release and fat intake in normal mice and 2) metabolic disorders in high-fat diet (HFD)-fed ob/ob mice, a model of severe obesity and type 2 diabetes mellitus, using an orally bioavailable MGAT2 inhibitor Compound B (CpdB).
|
31837122 |
2020 |
|
Impaired glucose tolerance
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Mogat2(IKO) mice increased energy expenditure although to a lesser degree than Mogat2(-/-) mice and were protected against diet-induced weight gain and associated comorbidities, including hepatic steatosis, hypercholesterolemia, and glucose intolerance.
|
24784138 |
2014 |